KR102391511B1 - 날트렉손 요법에서 약물 생체이용률의 증가 - Google Patents

날트렉손 요법에서 약물 생체이용률의 증가 Download PDF

Info

Publication number
KR102391511B1
KR102391511B1 KR1020217015625A KR20217015625A KR102391511B1 KR 102391511 B1 KR102391511 B1 KR 102391511B1 KR 1020217015625 A KR1020217015625 A KR 1020217015625A KR 20217015625 A KR20217015625 A KR 20217015625A KR 102391511 B1 KR102391511 B1 KR 102391511B1
Authority
KR
South Korea
Prior art keywords
naltrexone
pharmaceutically acceptable
acceptable salt
bupropion
food
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217015625A
Other languages
English (en)
Korean (ko)
Other versions
KR20210063473A (ko
Inventor
숀 플래나간
에두아르도 듀나예비치
Original Assignee
오렉시젠 세러퓨틱스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46172304&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102391511(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 오렉시젠 세러퓨틱스 인크. filed Critical 오렉시젠 세러퓨틱스 인크.
Publication of KR20210063473A publication Critical patent/KR20210063473A/ko
Application granted granted Critical
Publication of KR102391511B1 publication Critical patent/KR102391511B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M21/00—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physics & Mathematics (AREA)
  • Acoustics & Sound (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
KR1020217015625A 2010-12-03 2011-12-02 날트렉손 요법에서 약물 생체이용률의 증가 Active KR102391511B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US41939510P 2010-12-03 2010-12-03
US61/419,395 2010-12-03
KR1020207011510A KR102258043B1 (ko) 2010-12-03 2011-12-02 날트렉손 요법에서 약물 생체이용률의 증가
PCT/US2011/063177 WO2012075459A1 (en) 2010-12-03 2011-12-02 Increasing drug bioavailability in naltrexone therapy

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020207011510A Division KR102258043B1 (ko) 2010-12-03 2011-12-02 날트렉손 요법에서 약물 생체이용률의 증가

Publications (2)

Publication Number Publication Date
KR20210063473A KR20210063473A (ko) 2021-06-01
KR102391511B1 true KR102391511B1 (ko) 2022-04-26

Family

ID=46172304

Family Applications (5)

Application Number Title Priority Date Filing Date
KR1020217015625A Active KR102391511B1 (ko) 2010-12-03 2011-12-02 날트렉손 요법에서 약물 생체이용률의 증가
KR1020187016354A Active KR101984500B1 (ko) 2010-12-03 2011-12-02 날트렉손 요법에서 약물 생체이용률의 증가
KR1020197014576A Active KR102105857B1 (ko) 2010-12-03 2011-12-02 날트렉손 요법에서 약물 생체이용률의 증가
KR1020207011510A Active KR102258043B1 (ko) 2010-12-03 2011-12-02 날트렉손 요법에서 약물 생체이용률의 증가
KR1020137017317A Ceased KR20140035320A (ko) 2010-12-03 2011-12-02 날트렉손 요법에서 약물 생체이용률의 증가

Family Applications After (4)

Application Number Title Priority Date Filing Date
KR1020187016354A Active KR101984500B1 (ko) 2010-12-03 2011-12-02 날트렉손 요법에서 약물 생체이용률의 증가
KR1020197014576A Active KR102105857B1 (ko) 2010-12-03 2011-12-02 날트렉손 요법에서 약물 생체이용률의 증가
KR1020207011510A Active KR102258043B1 (ko) 2010-12-03 2011-12-02 날트렉손 요법에서 약물 생체이용률의 증가
KR1020137017317A Ceased KR20140035320A (ko) 2010-12-03 2011-12-02 날트렉손 요법에서 약물 생체이용률의 증가

Country Status (27)

Country Link
US (1) US20130245056A1 (cg-RX-API-DMAC7.html)
EP (5) EP4349369B1 (cg-RX-API-DMAC7.html)
JP (4) JP6008866B2 (cg-RX-API-DMAC7.html)
KR (5) KR102391511B1 (cg-RX-API-DMAC7.html)
CN (1) CN103313711A (cg-RX-API-DMAC7.html)
AR (2) AR093182A1 (cg-RX-API-DMAC7.html)
AU (2) AU2011336304B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013013390A2 (cg-RX-API-DMAC7.html)
CA (2) CA2819262C (cg-RX-API-DMAC7.html)
CL (1) CL2013001564A1 (cg-RX-API-DMAC7.html)
CY (2) CY1118968T1 (cg-RX-API-DMAC7.html)
DK (4) DK4349369T3 (cg-RX-API-DMAC7.html)
ES (3) ES2866879T3 (cg-RX-API-DMAC7.html)
FI (2) FI3884947T3 (cg-RX-API-DMAC7.html)
HR (4) HRP20251576T1 (cg-RX-API-DMAC7.html)
HU (3) HUE053831T2 (cg-RX-API-DMAC7.html)
IL (4) IL330443A (cg-RX-API-DMAC7.html)
LT (4) LT3222280T (cg-RX-API-DMAC7.html)
MX (2) MX384662B (cg-RX-API-DMAC7.html)
PL (4) PL3222280T3 (cg-RX-API-DMAC7.html)
PT (4) PT3222280T (cg-RX-API-DMAC7.html)
RS (4) RS67527B1 (cg-RX-API-DMAC7.html)
RU (1) RU2640561C2 (cg-RX-API-DMAC7.html)
SI (4) SI3222280T1 (cg-RX-API-DMAC7.html)
SM (4) SMT202100227T1 (cg-RX-API-DMAC7.html)
TW (1) TWI618536B (cg-RX-API-DMAC7.html)
WO (1) WO2012075459A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101167579B1 (ko) 2003-04-29 2012-07-27 오렉시젠 세러퓨틱스 인크. 체중감량용 조성물
PT2135603E (pt) 2005-11-22 2013-04-03 Orexigen Therapeutics Inc Composições e métodos para aumentar a sensibilidade à insulina
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
CA2725930A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
ES2762113T3 (es) 2010-01-11 2020-05-22 Nalpropion Pharmaceuticals Inc Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor
PT3222280T (pt) * 2010-12-03 2021-04-22 Nalpropion Pharmaceuticals Llc Aumento da biodisponibilidade farmacológica numa terapêutica com naltrexona
PL4104824T3 (pl) 2012-06-06 2025-11-12 Nalpropion Pharmaceuticals Llc Kompozycja do zastosowania w sposobie leczenia nadwagi i otyłości u pacjentów z wysokim ryzykiem sercowo-naczyniowym
US20180015042A1 (en) * 2015-02-07 2018-01-18 Intas Pharmaceuticals Ltd. Pharmaceutical composition for the treatment of obesity
CA3083850A1 (en) * 2017-03-28 2019-10-04 LDN Pharma Limited An agent that increases the expression of the bcl2-associated agonist of cell death for the treatment of cancer
EP3482751A1 (en) 2017-11-14 2019-05-15 LDN Pharma Limited Cancer treatment
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080013026A1 (en) 2006-06-30 2008-01-17 Lg Philips Lcd Co., Ltd. In-plane switching mode liquid crystal display device and method of fabricating the same
US20080058407A1 (en) 2006-07-20 2008-03-06 Cara Baron Methods of improving the pharmacokinetics of doxepin

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10129265A1 (de) * 2001-06-18 2003-01-02 Hf Arzneimittelforsch Gmbh Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie
US6972291B2 (en) * 2002-07-02 2005-12-06 Bernstein Richard K Method for reducing food intake
EP1772147A2 (en) * 2003-03-17 2007-04-11 Japan Tobacco, Inc. Method for increasing the oral bioavailability of S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]-2-methylpropanethioate
KR101167579B1 (ko) 2003-04-29 2012-07-27 오렉시젠 세러퓨틱스 인크. 체중감량용 조성물
JP2009502931A (ja) 2005-07-27 2009-01-29 オレキシジェン・セラピューティクス・インコーポレーテッド 体重減少を促すための組成物
US8921344B2 (en) * 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
PT2135603E (pt) 2005-11-22 2013-04-03 Orexigen Therapeutics Inc Composições e métodos para aumentar a sensibilidade à insulina
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
JP2009517393A (ja) 2005-11-28 2009-04-30 オレキシジェン・セラピューティクス・インコーポレーテッド 不安症の治療方法
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
SI2484346T1 (sl) 2006-06-19 2017-05-31 Alpharma Pharmaceuticals Llc Farmacevtski sestavki
DE602007005402D1 (de) * 2006-11-09 2010-04-29 Orexigen Therapeutics Inc Mehrschichtige pharmazeutische formulierungen mit einer schnell auflösenden zwischenschicht
WO2008060964A2 (en) * 2006-11-09 2008-05-22 Orexigen Therapeutics, Inc. Unit dosage package and methods for administering weight loss medications
KR20160065998A (ko) * 2007-04-11 2016-06-09 바이오마린 파머수티컬 인크. 테트라하이드로바이오프테린 투여 방법, 관련 조성물 및 측정 방법
DE102007036076A1 (de) 2007-08-01 2009-02-05 Bayer Healthcare Aktiengesellschaft Dipeptoid-Produgs und ihre Verwendung
US8318813B2 (en) * 2007-09-13 2012-11-27 Lcs Group, Llc Method of treating binge eating disorder
CA2725930A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
PT3222280T (pt) * 2010-12-03 2021-04-22 Nalpropion Pharmaceuticals Llc Aumento da biodisponibilidade farmacológica numa terapêutica com naltrexona

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080013026A1 (en) 2006-06-30 2008-01-17 Lg Philips Lcd Co., Ltd. In-plane switching mode liquid crystal display device and method of fabricating the same
US20080058407A1 (en) 2006-07-20 2008-03-06 Cara Baron Methods of improving the pharmacokinetics of doxepin

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Thomas A. Wadden 외. Obesity (Silver Spring). 2011년, Vol. 19, No. 1, pp. 110-120

Also Published As

Publication number Publication date
PT3884947T (pt) 2024-02-16
US20130245056A1 (en) 2013-09-19
KR20200044158A (ko) 2020-04-28
RS65198B1 (sr) 2024-03-29
HUE034393T2 (en) 2018-02-28
EP2646031A4 (en) 2014-04-23
TW201304780A (zh) 2013-02-01
KR20140035320A (ko) 2014-03-21
MX356801B (es) 2018-06-13
CN103313711A (zh) 2013-09-18
JP7025319B2 (ja) 2022-02-24
EP3884947A1 (en) 2021-09-29
MX2013006071A (es) 2013-10-01
AR093182A1 (es) 2015-05-27
PL3884947T3 (pl) 2024-05-06
KR101984500B1 (ko) 2019-05-31
AU2011336304B2 (en) 2017-03-30
IL270841A (en) 2020-01-30
KR20210063473A (ko) 2021-06-01
DK3884947T3 (da) 2024-01-22
EP2646031B1 (en) 2017-02-22
DK4349369T3 (da) 2025-12-22
DK2646031T3 (en) 2017-05-22
EP3222280A1 (en) 2017-09-27
CL2013001564A1 (es) 2014-05-02
KR102105857B1 (ko) 2020-05-04
HUE053831T2 (hu) 2021-07-28
BR112013013390A2 (pt) 2016-09-06
CA2819262A1 (en) 2012-06-07
RU2640561C2 (ru) 2018-01-09
JP2013544290A (ja) 2013-12-12
HRP20251576T1 (hr) 2026-01-30
LT3884947T (lt) 2024-03-12
JP2019056004A (ja) 2019-04-11
EP4696322A3 (en) 2026-04-15
IL330443A (en) 2026-08-01
AU2011336304A1 (en) 2013-07-11
ES3056642T3 (en) 2026-02-23
JP6008866B2 (ja) 2016-10-19
SMT201700232T1 (it) 2017-07-18
EP4349369A2 (en) 2024-04-10
LT4349369T (lt) 2026-01-12
KR102258043B1 (ko) 2021-05-28
SI2646031T1 (sl) 2017-07-31
WO2012075459A1 (en) 2012-06-07
HRP20240115T1 (hr) 2024-06-07
KR20180069089A (ko) 2018-06-22
FI4349369T3 (fi) 2025-12-17
RU2017144631A3 (cg-RX-API-DMAC7.html) 2021-04-13
KR20190058702A (ko) 2019-05-29
SI3222280T1 (sl) 2021-11-30
IL226504B (en) 2021-01-31
EP3884947B1 (en) 2023-11-15
ES2866879T3 (es) 2021-10-20
HRP20210618T1 (hr) 2021-09-17
JP2022060331A (ja) 2022-04-14
PL3222280T3 (pl) 2021-11-29
CA3239386A1 (en) 2012-06-07
LT2646031T (lt) 2017-06-26
JP2016210809A (ja) 2016-12-15
PT4349369T (pt) 2025-12-17
HUE065852T2 (hu) 2024-06-28
EP4696322A2 (en) 2026-02-18
ES2625527T9 (es) 2018-09-25
SMT202400038T1 (it) 2024-03-13
EP4349369B1 (en) 2025-09-17
CA2819262C (en) 2024-05-28
SI4349369T1 (sl) 2026-02-27
ES2625527T3 (es) 2017-07-19
CY1118968T1 (el) 2018-01-10
PL2646031T3 (pl) 2017-08-31
RS56014B1 (sr) 2017-09-29
FI3884947T3 (fi) 2024-01-30
EP2646031B9 (en) 2018-01-10
SMT202500474T1 (it) 2026-01-12
TWI618536B (zh) 2018-03-21
RU2013127423A (ru) 2015-01-10
PT2646031T (pt) 2017-05-25
JP2024071605A (ja) 2024-05-24
PT3222280T (pt) 2021-04-22
RS67527B1 (sr) 2026-01-30
AU2017204309A1 (en) 2017-07-13
EP2646031A1 (en) 2013-10-09
MX384662B (es) 2025-03-14
RU2017144631A (ru) 2019-02-18
SI3884947T1 (sl) 2024-06-28
EP3222280B1 (en) 2021-01-20
CY1124331T1 (el) 2022-07-22
EP4349369A3 (en) 2024-05-15
RS62149B1 (sr) 2021-08-31
AR124500A2 (es) 2023-04-05
JP6456890B2 (ja) 2019-01-23
LT3222280T (lt) 2021-05-10
DK3222280T3 (da) 2021-04-19
IL279626A (en) 2021-03-01
PL4349369T3 (pl) 2026-03-23
HRP20170734T1 (hr) 2017-08-11
SMT202100227T1 (it) 2021-07-12

Similar Documents

Publication Publication Date Title
JP7025319B2 (ja) ナルトレキソン療法における薬物バイオアベイラビリティの増加
US20220233520A1 (en) Increasing Drug Bioavailability In Naltrexone Therapy
RU2781141C2 (ru) Повышение биодоступности лекарственных средств при терапии налтрексоном
HK1188136A (en) Increasing drug bioavailability in naltrexone therapy
HK1188136B (en) Increasing drug bioavailability in naltrexone therapy

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 5